Founded in 2005 in Guangzhou, China's thriving innovation hub, Guangzhou Wexis Biotech Limited ("Wexis") is a nationally recognized leader in comprehensive histopathology solutions. We design and manufacture precision instruments, advanced reagents, and specialised consumables that streamline the entire diagnostic workflow—from tissue processing to analysis.

In recent years, the company has implemented a four-wheel drive strategy of "R&D - intelligent manufacturing - service - capital", expanding its international market and achieving global layout through measures such as increasing R&D investment, promoting NASDAQ listing in the United States, and establishing a European service system

At Wexis, we recognize that sustainability is no longer optional but essential. That's why we integrate eco-conscious practices into our product development and operations, ensuring our solutions meet both the evolving demands of laboratories and the imperative for environmental responsibility.

Vision: 

To be a global leader in biotechnological innovation, driving breakthroughs in health and life sciences to create a healthier, more sustainable world for future generations.

Mission: 

We are dedicated to advancing biotechnology through cutting-edge research, sustainable practices, and collaboration. We strive to develop transformative solutions that enhance human health, address global health challenges, and improve the quality of life through innovation, excellence, and responsibility.

Our Commitment to Excellence

Guided by 20 years of experience, the pillars of our continued growth and success are based on the following;

1. Quality

Zero-compromise quality philosophy, underpinned by Internationally recognised certifications e.g. IVDR compliance. Wexis is also ISO13485 certified and is one of the national pathology training bases designated by the Pathology Equipment Branch of the China Medical Equipment Association (only 5 enterprises in the country have obtained this qualification).

2. Innovation

Our 30+ R&D team of pathology experts and engineers have enabled us to currently hold 6 invention patents and 40+ utility patents. Our strategic vision is to bring innovative and also sustainable technology-based products to market. Wexis has 62 patents and has invested over 10% in research and development (R&D) in the past three years.

3. Sustainability 

Our teams are targeted to develop and promote sustainable products that reduce environmental impact. 

Corporate Responsibility highlights Wexis’ commitment to sustainability and social responsibility in marketing materials and communications.

4. Supplier and Customer Support

At Wexis Biotech, we believe exceptional customer service and technical support are the foundation of strong partnerships. Our dedicated global team provides suppliers and end-users with responsive and personalised assistance.

5. Global Expansion Strategy

Wexis has launched a three-pronged globalisation strategy:

·        a) Global Sales Initiative

Our vision and mission is to become a world-leading innovator and supplier in the Anatomical Pathology sector. 

·        b) Advanced Manufacturing 

With increasing investment, our Zengcheng Smart Manufacturing Base in Guangzhou will be focusing on bringing to market a steady stream of innovative and sustainable offerings.

·        c) Global Sales and Service Support network Initiative

Our forward-thinking plan is to increase our support network internationally.